Pfizer enlists entire town in Brazil to study ongoing efficacy of its Covid vaccine
Toledo town, where the study will be conducted, has little to account for in terms of vaccine hesitancy
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An entire town in Brazil will be inoculated by pharmaceutical company Pfizer to study the transmission of the coronavirus in a vaccinated population.
The study will be carried out among those above the age of 12 in the town of Toledo, west of the country’s Parana state, according to the company.
“The initiative is the first and only of its kind to be undertaken in collaboration with the pharmaceutical company in a developing country,” Pfizer said on Wednesday.
The observational study will help researchers find out the “real-life scenario” of the transmission of the coronavirus once an entire population is vaccinated.
It will aim to validate the real-world efficacy and safety of the Pfizer vaccine seen in clinical trials, Regis Goulart, a researcher at Porto Alegre’s Moinhos de Vento hospital, told Reuters.
Participants will be monitored for a year and will help answer questions such as the emergence of new variants and how long vaccines will prove to protect against Covid-19, Mr Goulart added.
The study will be done in partnership with Brazil’s national vaccination programme, local health authorities, a federal university and the Moinhos de Vento hospital.
Toledo, where the study will take place, has a population of 143,000 and little to account for in terms of vaccine hesitancy.
At least 98 per cent of its population has already received a first dose of a vaccine, primarily Pfizer, reported Reuters.
Around 56 per cent of the town is also fully vaccinated, with AstraZeneca and Sinovac vaccines being used as well, said municipal health secretary Gabriela Kucharski.
“Here we believe in science and we lament the almost 600,000 deaths from COVID-19 in Brazil,” Beto Lunitti, the town’s mayor, said at a press conference announcing the Pfizer study.
A similar study was earlier conducted in the smaller town of Serrana in Sao Paulo state. The study tested the CoronaVac jab, developed by China’s Sinovac Biotech.
Butantan Institute, a leading biomedical research centre in Brazil which conducted the study, said in May that mass vaccination reduced Covid-19 deaths by 95 per cent in the town, which has a population of 45,644 people.
The institute is considering extending the study for a third dose, according to Reuters.
Additional reporting by agencies
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments